Drugs / pegylated liposomal doxorubicin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02272790 | Jan 2015 → Dec 2018 | neoplastic disease or syndrome | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pegylated liposomal doxorubicin | “PLD (pegylated liposomal doxorubicin) 40 mg/m² IV will be given on Day 1 of each 28-Day cycle.” NCT02272790 ↗ |
| Known as | PLD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02272790 ↗ |